Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Ms Robin Klebig and Dr Matthew Lunning. Published June 16, 2023. (Symposium Video Proceedings)
TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of diffuse large B-cell lymphoma (DLBCL).
PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with DLBCL.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
CREDIT DESIGNATION STATEMENT
NCPD credit is no longer available for this issue
ONCC/ILNA CERTIFICATION INFORMATION
NCPD credit is no longer available for this issue
FOR SUCCESSFUL COMPLETION
Video Program: This NCPD activity consists of a video component.
NCPD credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Christopher R Flowers, MD, MS
Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas
Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Epizyme Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Spectrum Pharmaceuticals Inc; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor, ZIOPHARM Oncology Inc; Nonrelevant Financial Relationship: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, National Cancer Institute.
Amy Goodrich, CRNP
Nurse Practitioner
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland
No relevant conflicts of interest to disclose.
Robin Klebig, APRN, CNP, AOCNP
Hematology Outpatient APP Supervisor
Assistant Professor of Medicine
Nurse Practitioner, Lymphoma Group
Division of Hematology
Mayo Clinic
Rochester, Minnesota
No relevant conflicts of interest to disclose.
Matthew Lunning, DO
Associate Professor
Medical Director, Cellular Therapy
Assistant Vice Chair of Research, Department of Medicine
Assistant Vice Chancellor for Clinical Research
Fred and Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska
Consulting Agreements: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, CRISPR Therapeutics, Daiichi Sankyo Inc, EUSA Pharma, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Instil Bio, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, MorphoSys, Novartis, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc; Contracted Research: Bristol Myers Squibb, Curis Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc and AbbVie Inc, and Incyte Corporation.
Release date: June 2023
Expiration date: June 2024
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.
(WIFI is recommended for best performance):